Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomised, Double Blind, Placebo-Controlled, Parallel Arm, Multi-Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for Twelve Weeks, Compared to Placebo, in Asthmatics Symptomatic on Low Dose ICS

NCT03622112 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03622112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03622112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomised, Double Blind, Placebo-Controlled, Parallel Arm, Multi-Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for Twelve Weeks, Compared to Placebo, in Asthmatics Symptomatic on Low Dose ICS
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
January 2, 2019
Completion date
September 30, 2019
Enrollment
808 (actual)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

asthma